Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Why Shares of TG Therapeutics Soared on Tuesday: https://g.foolcdn.com/editorial/images/727875/physician-going-over-results-with-patient-1.jpg
Why Shares of TG Therapeutics Soared on Tuesday

Shares of TG Therapeutics (NASDAQ: TGTX) were up by 18% as of mid-afternoon Tuesday after reports that the biotech's multiple sclerosis therapy Briumvi would have better-than-expected sales in its

TheMotleyFool 
0 11.04.23
Why Tilray Stock Sank and Moved the Canadian Cannabis Market Today: https://g.foolcdn.com/editorial/images/727842/marijuanabudsdispensary.jpg
Why Tilray Stock Sank and Moved the Canadian Cannabis Market Today

Tilray Brands (NASDAQ: TLRY) shook up the cannabis sector with its third-quarter fiscal 2023 earnings report last night. But it wasn't the results that many were focused on, as both Tilray and

TheMotleyFool 
0 11.04.23
Why Shares of Adaptimmune Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/727860/dna-genetic-sequencing-biotech-1.jpg
Why Shares of Adaptimmune Therapeutics Jumped Tuesday

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the

TheMotleyFool 
0 11.04.23
Is Tilray Stock a Buy With Its Acquisition of Hexo?: https://g.foolcdn.com/editorial/images/727770/cannabis-man-in-greenhouse.jpg
Is Tilray Stock a Buy With Its Acquisition of Hexo?

Some corporate buyouts come as a total shock. Others aren't surprising in the least. I think you can include Tilray Brands' (NASDAQ: TLRY) planned acquisition of Hexo (NASDAQ: HEXO) in the latter

TheMotleyFool 
0 11.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 11.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 10.04.23
EQS-News: Evotec SE provides update on cyber attack: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE provides update on cyber attack
EQS-News: Evotec SE provides update on cyber attack
eqs_en 
0 10.04.23
EQS-Adhoc: Cyber Attack on Evotec: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Cyber Attack on Evotec
EQS-Adhoc: Cyber Attack on Evotec
eqs_en 
0 07.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 06.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 05.04.23
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
eqs_en 
0 04.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 04.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 03.04.23
EQS-Adhoc: PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-Adhoc: PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
EQS-Adhoc: PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
eqs_en 
0 03.04.23
EQS-News: PAION AG implements resolved capital reduction: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG implements resolved capital reduction
EQS-News: PAION AG implements resolved capital reduction
eqs_en 
0 31.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 31.03.23
EQS-News: SARTORIUS AG: Sartorius to acquire Polyplus: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: Sartorius to acquire Polyplus
EQS-News: SARTORIUS AG: Sartorius to acquire Polyplus
eqs_en 
0 31.03.23
AEVIS VICTORIA SA – Publication of the Annual Report 2022http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Publication of the Annual Report 2022
AEVIS VICTORIA SA – Publication of the Annual Report 2022
eqs_en 
0 31.03.23
EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 16.05.2023 according to article 121 AktG (German St: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 16.05.2023 according to article 121 AktG (German St
EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 16.05.2023 according to article 121 AktG (German St
eqs_en 
0 30.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 30.03.23
EQS-News: Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency
EQS-News: Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency
eqs_en 
0 30.03.23
EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2022
EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2022
eqs_en 
0 30.03.23
EQS-News: PAION AG reports on fiscal year 2022: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG reports on fiscal year 2022
EQS-News: PAION AG reports on fiscal year 2022
eqs_en 
0 30.03.23
EQS-News: STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
EQS-News: STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
EQS-News: STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
eqs_en 
0 30.03.23
EQS-News: SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division
EQS-News: SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division
eqs_en 
0 29.03.23